SELLAS Life Sciences Group, Inc. $SLS Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 73.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 597,309 shares of the company’s stock after purchasing an additional 252,531 shares during the period. Wellington Management Group LLP’s holdings in SELLAS Life Sciences Group were worth $8,816,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of SELLAS Life Sciences Group by 86.6% in the 1st quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock valued at $2,023,000 after purchasing an additional 221,957 shares in the last quarter. Bank of America Corp DE boosted its position in SELLAS Life Sciences Group by 535.7% during the first quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock worth $2,714,000 after purchasing an additional 540,748 shares in the last quarter. Dagco Inc. grew its holdings in SELLAS Life Sciences Group by 19.8% in the second quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after purchasing an additional 203,653 shares during the period. Quantinno Capital Management LP purchased a new stake in shares of SELLAS Life Sciences Group in the first quarter valued at approximately $315,000. Finally, Fifth Third Bancorp purchased a new stake in shares of SELLAS Life Sciences Group in the first quarter valued at approximately $253,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Price Performance

NASDAQ SLS opened at $13.96 on Wednesday. The company has a market cap of $2.82 billion, a PE ratio of -66.47 and a beta of 2.52. The stock’s 50 day simple moving average is $12.80 and its 200-day simple moving average is $8.61. SELLAS Life Sciences Group, Inc. has a 1-year low of $1.39 and a 1-year high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.